HOME >> MEDICINE >> NEWS
Daytrana provides significant effectiveness in both boys and girls with ADHD

SAN DIEGO MAY 23, 2007 Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that DAYTRANA (methylphenidate transdermal system), its Attention Deficit Hyperactivity Disorder (ADHD) patch, had significant efficacy in reducing the symptoms of ADHD in both male and female children aged 6 to 12 years, according to clinical trial results reported at the American Psychiatric Association (APA) annual meeting in San Diego.

"Few clinical studies have examined gender differences in the response to ADHD treatments. Our study documented that DAYTRANA offered a favorable safety profile and was an effective ADHD treatment in both boys and girls," said Robert Findling, M.D., lead investigator and Professor of Psychiatry at Case Western Reserve University and Director of the Division of Adolescent and Child Psychiatry at University Hospitals Case Medical Center. "The study provides a platform to open a dialogue about gender and ADHD."

Approximately 4.4 million U.S. children aged 4 to 17 years -- about 7.8 percent of all school-age children -- have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). Studies estimated that 11.0 percent of boys have been diagnosed with ADHD in contrast to only 4.4 percent of girls. Experts believe that girls with ADHD are underdiagnosed and, therefore, undertreated.

Shire's DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. DAYTRANA is available in four dosage strengths 10 mg, 15 mg, 20 mg and 30 mg all designed for once-daily use. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because Daytrana is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired
'"/>

Contact: Marion E. Glick
212-601-8273
Porter Novelli
23-May-2007


Page: 1 2

Related medicine news :

1. 12-month study demonstrated tolerability and efficacy of Daytrana
2. Sports concussion research using fMRI provides insight for safe return-to-play decisions
3. Fluorescence diffuse optical tomography provides high contrast, 3-D look at breast cancer
4. New book provides unprecedented look at role of religion over a lifetime
5. New edition of medical reference book provides the latest in hematology
6. Lung cancer screening regimen provides opportunity for cure
7. MERLIN TIMI-36 study provides new safety and efficacy data for unique anti-anginal therapy
8. IceSAR campaign provides glimpse of future Sentinel-1 images over ice
9. Darunavir with FUZEON provides HIV patients a better chance to reach undetectable viral load
10. Optical technique provides improved virtual biopsies of internal surfaces
11. Enbrel provides sustained clinical improvements for ankylosing spondylitis for up to 3 years

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/17/2019)... ... September 17, 2019 , ... ... "Pacifica Experience" Open House day on Pacifica's Lambert Campus, 249 Lambert Road, ... Depth Psychology, the Humanities, Clinical Psychology, Counseling Psychology, and Mythological Studies. Program ...
(Date:9/12/2019)... Ohio (PRWEB) , ... September 12, 2019 , ... ... on both a local and national scale in two recent and well-renowned listing ... country’s fastest-growing privately held businesses for the 2019 year. , Dr. Jeffrey ...
(Date:9/11/2019)... ... , ... A September 2 article on CBS News details a ... likely to suffer heart attacks, strokes, kidney failure, and heart disease versus a control ... surgery specialists Dr. Feiz and Associates says the study adds further evidence to an ...
(Date:9/11/2019)... (PRWEB) , ... September 11, 2019 , ... ... will exhibit at the 2019 AHIMA Health Data and Information Conference in Chicago, ... stop by booth #505 to learn more about GRM’s healthcare information management ...
(Date:9/11/2019)... ... September 11, 2019 , ... ... challenges facing specialty healthcare, announces the issuance of a patent to reduce the ... payment plan for both time-of-service and post visit patient statements. , At the ...
Breaking Medicine News(10 mins):
(Date:9/14/2019)... (PRWEB) , ... September 14, 2019 , ... ... of four plaintiffs living with peritoneal mesothelioma, a jury in Middlesex County found ... consolidated trial of plaintiffs alleging their mesotheliomas were caused by asbestos-containing J&J talc ...
(Date:9/12/2019)... CITY (PRWEB) , ... September 12, 2019 , ... ... are collaborating to help make the services of CPESN’s clinically integrated network of ... and payers. CPESN USA’s participating pharmacies provide high quality clinical service programs ...
(Date:9/11/2019)... FALLS CHURCH, Va. (PRWEB) , ... September 11, ... ... explosion is revolutionizing image analysis, with many companies developing technologies to evaluate medical ... segments. , Unless one understands the approaches the FDA is taking to AI-based ...
Breaking Medicine Technology:
Cached News: